New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2013
12:18 EDTGILDGilead announces 24-week Phase 2 results for once-daily HIV regimen
Gilead Sciences announced detailed 24-week results from a Phase 2 study evaluating a once-daily single tablet regimen containing tenofovir alafenamide for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented today in a latebreaker session at the 20th Conference on Retroviruses and Opportunistic Infections taking place in Atlanta. In Study 102, HIV-positive treatment-na´ve adult patients were randomized to receive the investigational TAF-based regimen or Stribild. At 24 weeks, 87% of patients taking TAF and 90% of patients taking Stribild achieved HIV RNA less than 50 copies/mL, based on the FDA snapshot algorithm. There were no statistically significant differences in the frequency and nature of Grades 3-4 laboratory abnormalities, and the frequency and nature of adverse events were similar between the two arms. Both regimens were generally well tolerated.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
November 24, 2014
16:00 EDTGILDOptions Update; November 24, 2014
Subscribe for More Information
10:16 EDTGILDGilead management to meet with ISI Group
Meeting to be held in Scotland on December 1 hosted by ISI Group.
09:39 EDTGILDActive equity options trading
Subscribe for More Information
November 21, 2014
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN TSLA BIDU CLF DOW LVS BABA TWTR GILD
November 20, 2014
15:44 EDTGILDOptions Update; November 20, 2014
Subscribe for More Information
11:21 EDTGILDGilead calls active on renewed activist investor speculation
Gilead November 101 and 103 calls are active on 14K contracts (2K puts) on renewed activist investor speculation. November call option implied volatility is at 38, December is at 36, and January is at 35; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
11:11 EDTGILDRumor: Gilead moves up on renewed activiest investor speculation
Shares of Gilead are moving higher on speculation that Carl Icahn has taken a stake in the company.
November 19, 2014
07:33 EDTGILDGilead Q4 HCV sales likely to reach at least $3.5B, says Wells Fargo
Subscribe for More Information
November 18, 2014
16:00 EDTGILDOptions Update; November 18, 2014
iPath S&P 500 VIX Short-Term Futures down 48c to 28.09. Option volume leaders: AAPL TSLA TWTR KO PBR GILD according to Track Data.
10:08 EDTGILDGilead granted European Commission marketing authorization for Harvoni
Subscribe for More Information
November 17, 2014
16:00 EDTGILDOptions Update; November 17, 2014
Subscribe for More Information
11:06 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL PBR BHI GILD MU HD AMZN TSLA YHOO FB TWTR
November 14, 2014
14:53 EDTGILDCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
11:48 EDTGILDStocks with call strike movement; GILD BBY
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
November 13, 2014
13:32 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use